Device Trial Radar · NCT02539056
The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Oct 15, 2012
Primary completion
Mar 18, 2016
Study completion Mar 18, 2016
Sponsor
- Lead sponsor
- Cellontech Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 2, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical trial to evaluate the long-term efficacy and safety of a CHONDRON (Autologous cultured Chondrocyte) for 48weeks, and additional 96weeks in patients with cartilage defects in their knees.
Conditions
- Osteoarthritis
- Traumatic Arthritis
Interventions
Chondron ImplantationDevice
In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in pain of 100mm Visual Analog ScaleTime frame: 48 weeks after the surgery
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Inha Univerisity Hospital
Incheon, Incheon, South Korea
Ewha Womans University Mokdong Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.